Condition: AML, Childhood · Relapse/Recurrence · Refractory AML · Sponsor: Children's Hospital of Soochow University
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
This description comes directly from the study's public registry record.
Shaoyan Hu, MD, PhD · +86-13771870462 · hsy139@126.com
Li Gao, MD · +86-15821963190 · joygaoli@163.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital Of University of Science and Technology of China | Hefei, Anhui, China | Not Yet Recruiting |
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Guangzhou Women and Children Medical Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Not Yet Recruiting |
| Kaifeng Children's Hospital | Kaifeng, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Third Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| XiangYa Hospital Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| Children's Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Xuzhou Children's Hospital | Xuzhou, Jiangsu, China | Not Yet Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Not Yet Recruiting |
| Children's Hospital Of Fudan University | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06316960